Natera (NTRA) Stock Forecast & Price Target

Natera is viewed positively because it dominates the $15B+ MRD market with >90% share, and Signatera is driving about 60% volume growth in 2025 while management sees durable reimbursement expansion and growing clinical adoption. The outlook is further supported by margin leverage: current Signatera ASP of $1,275 is well below the $3,590 Medicare rate, COGS/test has fallen more than $100 since 2022, and the business is expected to move toward 70%+ gross margin and 25%+ EBIT over time. Additional upside comes from underappreciated catalysts in ultra-sensitive Signatera Genome, pharma trials and data licensing, and early cancer detection, where management sees a ~13M test TAM and a potential ~$1.5B revenue opportunity.

Natera is facing a negative fundamental setup because its growth story depends heavily on MRD penetration and ASP expansion, yet adoption in more established uses like CRC adjuvant already exceeds 50%, leaving limited incremental upside. The MRD market is becoming increasingly crowded, while Women’s Health also faces persistent competition, raising the risk that rivals erode share as Medicare reimbursement expands. In addition, catalysts have been inconsistent, with delayed guideline updates and failed trials, and the move in MRD ASPs from roughly $500 to $1,250 over the past five years may not continue smoothly toward the $2,000 goal.